skip to main content
Idioma:
Refinado por: Base de dados/Biblioteca: IngentaConnect Journals remover tipo de recurso: Outros remover Single Journals remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Alpelisib plus endocrine therapy in patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study
Alpelisib plus endocrine therapy in patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study
Material Type:
Outros 		Adicionar ao Meu Espaço

Alpelisib plus endocrine therapy in patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study

Chia, Stephen ; Neven, Patrick ; Ciruelos, Eva M ; Lerebours, Florence ; Ruiz-Borrego, Manuel ; Drullinsky, Pamela ; Prat, Aleix ; Park, Yeon Hee ; Juric, Dejan ; Turner, Nicholas C ; Chattar, Yogesh ; Patino, Heather ; Akdere, Murat ; Rugo, Hope S

JOURNAL OF CLINICAL ONCOLOGY, 2023, Vol.41 (16)

LIPPINCOTT WILLIAMS & WILKINS

Texto completo disponível

Citações Citado por
2
Safety and efficacy results from the expansion phase of the first-in-human study evaluating TGFß inhibitor SAR439459 alone and combined with cemiplimab in adults with advanced solid tumors
Safety and efficacy results from the expansion phase of the first-in-human study evaluating TGFß inhibitor SAR439459 alone and combined with cemiplimab in adults with advanced solid tumors
Material Type:
Outros 		Adicionar ao Meu Espaço

Safety and efficacy results from the expansion phase of the first-in-human study evaluating TGFß inhibitor SAR439459 alone and combined with cemiplimab in adults with advanced solid tumors

Robbrecht, Debbie ; Doger, Bernard ; Grob, Jean-Jacques ; Bechter, Oliver Edgar ; De Miguel, Maria J ; Vieito, Maria ; Schadendorf, Dirk ; Curigliano, Giuseppe ; Borbath, Ivan ; Butler, Marcus O ; Rodriguez-Vida, Alejo ; Miller, Wilson H ; Lin, Tun Tun ; Masson, Nina ; Pouzin, Clemence ; Wang, Rui ; Demers, Brigitte ; Amrate, Amele ; Abbadessa, Giovanni ; Simonelli, Matteo

JOURNAL OF CLINICAL ONCOLOGY, 2022, Vol.40 (16)

LIPPINCOTT WILLIAMS & WILKINS

Texto completo disponível

Citações Citado por
3
Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of HDM-2 antagonist JNJ-26854165 in patients with advanced refractory solid tumors
Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of HDM-2 antagonist JNJ-26854165 in patients with advanced refractory solid tumors
Material Type:
Outros 		Adicionar ao Meu Espaço

Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of HDM-2 antagonist JNJ-26854165 in patients with advanced refractory solid tumors

Tabernero, J ; Dirix, L ; Schöffski, Patrick ; Cervantes, A ; Capdevila, J ; Baselga, J ; van Beijsterveldt, L ; Winkler, H ; Kraljevic, S ; Zhuang, SH

Journal of Clinical Oncology, 2009, Vol.27 (15), p.3514-3514

Grune & Stratton

Texto completo disponível

Citações Citado por
4
Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease
Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease
Material Type:
Outros 		Adicionar ao Meu Espaço

Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease

Harrison, David G ; Cai, Hua ; Landmesser, Ulf ; Griendling, Kathy K

Journal of the renin-angiotensin-aldosterone system : JRAAS, 2003, Vol.4 (2), p.51-61

Texto completo disponível

Citações Citado por

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Refinar Meus Resultados

Data de Publicação 

De até
Refinar

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.